SAM
CRVS icon

SEB Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

SEB Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39M Hold
226,837
– – 0.01% 542
2026
Q1 		$3.32M Buy
+226,837
New +$3.62M 0.01% 520

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SEB Asset Management's CRVS Position: Q2 2026 in Review

SEB Asset Management held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 226,837 shares worth $3.39M. The position accounts for 0.01% of the portfolio, ranked #542.

SEB Asset Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • SEB Asset Management held 226,837 shares of Corvus Pharmaceuticals worth $3.39M as of Q2 2026.
  • SEB Asset Management left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
  • Corvus Pharmaceuticals made up 0.01% of SEB Asset Management's portfolio in Q2 2026, its #542 holding.
  • SEB Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 160 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.